Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. J of Skin. 2018;2:S80. doi:10.25251/skin.2.supp.81